Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma Meeting Abstract
| Authors: | Aggen, D.; McKean, M.; Lakhani, N.; Bashir, B.; Hoffman-Censits, J.; Alhalabi, O.; Guancial, E.; Bowman, I.; Tan, A.; Lingaraj, T.; Timothy, M.; Ortiz-Otero, N.; Bartolini, W.; Kacena, K.; Malek, K.; Santillana, S.; Luke, J. |
| Abstract Title: | Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma |
| Meeting Title: | 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 10 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Nov 8-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-11-01 |
| Start Page: | A692 |
| Language: | English |
| ACCESSION: | WOS:000919423400621 |
| DOI: | 10.1136/jitc-2022-SITC2022.0661 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 661 -- Source: Wos |
